Cost Effectiveness of Multi-Therapy Treatment Strategies in the Prevention of Vertebral Fractures in Postmenopausal Women with Osteoporosis
- 1 January 1998
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 14 (5) , 559-573
Abstract
Objective: The aim of this study was to evaluate the cost effectiveness of multitherapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis. Design: A retrospective, incremental cost-effectiveness analysis was conducted from a societal perspective. It compared 9 treatment strategies over 3 years and incorporated the willingness of patients to initiate and continue each therapy. Main outcome measures and results: Four nondominated strategies formed the efficient frontier in the following order: (i) calcium → no therapy; (ii) ovarian hormone therapy (OHT) → calcium → no therapy [166 Canadian dollars ($Can)]; (iii) OHT → etidronate → calcium → no therapy ($Can2331); and (iv) OHT → alendronate → calcium → no therapy ($Can40 965). The figures in parentheses are the incremental costs per vertebral fracture averted to move to that strategy from the previous strategy for patients who had undergone a hysterectomy. Conclusions: We identified 4 efficient multi-therapy strategies for the treatment of vertebral osteoporosis in postmenopausal women, 2 of which were consistent with the practice guidelines of the Osteoporosis Society of Canada. Decisionmakers may select from among these efficient strategies on the basis of incremental cost effectiveness.Keywords
This publication has 30 references indexed in Scilit:
- The Economics of Osteoporosis and Its PreventionPharmacoEconomics, 1997
- Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal OsteoporosisNew England Journal of Medicine, 1995
- Meta-analytic Tools for Medical Decision Making: A Practical GuideMedical Decision Making, 1995
- Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in post‐menopausal osteoporosisClinical Endocrinology, 1994
- Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapyThe American Journal of Medicine, 1993
- Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal WomenAnnals of Internal Medicine, 1992
- Treatment of Postmenopausal Osteoporosis with Transdermal EstrogenAnnals of Internal Medicine, 1992
- Effect of Fluoride Treatment on the Fracture Rate in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 1990
- Postmenopausal OsteoporosisMedical Clinics of North America, 1987
- Cost-Effectiveness of Hormone Replacement Therapy in the MenopauseObstetrical & Gynecological Survey, 1983